<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195922</url>
  </required_header>
  <id_info>
    <org_study_id>100180</org_study_id>
    <secondary_id>10-D-0180</secondary_id>
    <nct_id>NCT01195922</nct_id>
  </id_info>
  <brief_title>Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Advanced-stage head and neck cancer (head and neck squamous cell carcinoma [HNSCC]) has
      moderately successful treatment outcomes, usually involving surgery as part of the standard
      treatment. Researchers are investigating the use of the drug rapamycin to prevent tumor
      growth in HNSCC, and are interested in using it to treat individuals with HNSCC that has not
      been treated previously with other drugs, radiation, or surgery.

      Objectives:

      - To evaluate the usefulness of rapamycin in decreasing tumor size prior to surgery for head
      and neck squamous cell carcinoma.

      Eligibility:

      - Individuals at least 18 years of age who have been diagnosed with advanced head and neck
      squamous cell carcinoma that has not yet been treated.

      Design:

        -  Participants will be screened with a physical examination, medical history, blood tests,
           and imaging studies.

        -  Approximately 1 month before scheduled surgery, participants will begin to receive
           rapamycin. Participants will take rapamycin once daily for 21 days, followed by a 7-day
           period without the drug.

        -  During the 21-day rapamycin treatment, participants will have weekly study visits to
           provide blood and urine samples and have possible tumor biopsies and imaging studies
           such as x-rays or tumor photographs. Participants will have additional study visits for
           tests 1 day and 1 week after the end of rapamycin treatment, followed by HNSCC surgery.

        -  Participants will have a final visit to provide blood samples 30 days after surgery.

        -  Participants medical records will be reviewed 1 year after surgery; however,
           participants will not need to have further study visits at this time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

        -  The five-year survival rate for head and neck squamous cell carcinoma (HNSCC) has
           remained at approximately 50% for more than three decades.

        -  In HNSCC, the AKT-mTOR-pS6 pathway is aberrantly activated and promotes tumorigenesis
           and metastasis.

        -  Rapamycin is the most extensively studied mTOR inhibitor for which therapeutic daily
           oral dose and schedule, pharmacologic levels in blood, and safety have been established.

        -  Inhibition of mTOR by rapamycin causes the rapid apoptotic death of HNSCC tumor
           xenografts and decreases the tumor burden and prolongs the survival of mice harboring
           early and advanced oral and skin SCC lesions in a variety of experimental cancer models.

        -  Preliminary evidence suggests that mTOR inhibitors cause tumor shrinkage and improved
           tumor margins in HNSCC patients.

      OBJECTIVES:

        -  The primary objectives are to evaluate the following for patients with HNSCC given
           rapamycin as neoadjuvant treatment prior to surgery or chemoradiation:

             -  Whether therapeutic activities of rapamycin lead to inhibition of mTOR complexes,
                mTORC1 and mTORC2, as assessed by the change in levels of pS6 and pAkt473 measured
                by immunohistochemistry (IHC) in tumor samples and by Western blotting in
                peripheral blood mononuclear cells (PBMCs) and reduce tumor cell proliferation, as
                judged by IHC for Ki-67 in tumor samples.

             -  Antitumor activity in terms of objective response.

        -  Secondary objectives include safety evaluation of rapamycin therapy, exploratory studies
           of possible effects of rapamycin on tumor size, dynamic CT perfusion, and FDG-PET; and
           evaluation of tumor proliferation, apoptosis, microvessel density, and molecular changes
           associated with these effects. Survival status, recurrence of disease, metastases, and
           adverse events/serious adverse events, including complications of wound healing, which
           are related to rapamycin therapy will also be assessed for 360 days after surgery or
           chemoradiation through medical record review.

      ELIGIBILITY:

        -  Males and females age 18 years and older

        -  Previously untreated HNSCC of the oral cavity or oropharynx

        -  Clinical stage II, III, or IVA disease without distant metastasis

        -  Definitive therapy to include surgical resection or chemoradiation for curative purposes

        -  Life expectancy greater than six months

      STUDY DESIGN:

        -  Pilot, single arm, open-label, interventional neoadjuvant clinical trial.

        -  Twenty one evaluable subjects will take rapamycin (sirolimus) orally once per day for 21
           days.

        -  Before and after dosing, the tumor will be photographed and biopsied, peripheral blood
           mononuclear cells (PBMCs) will be collected, and computed tomography and positron
           emission tomography scans will be performed.

        -  Surgical or chemoradiation treatment, which is being provided outside of this protocol,
           will be conducted after Day 28 and when rapamycin levels are less than or equal to 3
           nanograms per milliter.

        -  Subjects will be followed by medical record review for 360 days after surgery or
           chemoradiation to assess 1) survival, 2) recurrence of disease, 3) metastases, and 4)
           adverse events/serious adverse events that are related to rapamycin therapy, including
           complications of wound healing and infections due to immune compromise.

        -  Levels of pS6 and pAkt473 in tumor tissue and PBMCs and Ki-67 in tumor tissue before and
           after rapamycin therapy will be determined by immunohistochemistry and by Western
           blotting. Computed tomography (CT) and positron emission tomography (PET) scans of the
           head, neck, and chest region with and without contrast will be performed within 7 days
           prior to the first rapamycin administration. One day after the last administration of
           rapamycin the CT and PET scans (head and neck region only) with contrast will be
           repeated.

        -  A single stage design will be used based on response defined as &gt; 25% tumor shrinkage. A
           Wilcoxon signed rank test will be used to compare levels of pS6, pAkt473, and Ki-67
           before and after rapamycin therapy. As part of secondary analysis, the number of
           subjects achieving a best response of complete response (CR), partial response (PR),
           stable disease (SD), or progressive disease (PD) according to Response Evaluation
           Criteria in Solid Tumors (RECIST) version 1.1 will also be summarized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (%) Change in Levels of pS6, pAKt473, and Ki-67</measure>
    <time_frame>21 days post treatment with rapamycin</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent (%) Changes in Tumor Size, Blood Flow, and Standardized Uptake Value</measure>
    <time_frame>21 days post treatment with rapamycin</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent (%) Change in Clinical and Laboratory Evaluations for Safety</measure>
    <time_frame>Percent (%) change from Pre to Post treatement (~21 days)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Mouth Neoplasms</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Tongue Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with sirolimus 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT &amp; amp; PET scans will be done for tumor measurement.</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  ELIGIBILITY CRITERIA:

        Males and females and members of any race or ethnic group who meet the eligibility criteria
        may participate in this trial.

        INCLUSION CRITERIA:

        Participants must meet all of the following inclusion criteria:

          1. Age 18 years and older

          2. Histologically confirmed previously untreated squamous cell carcinoma o f the oral
             cavity or oropharynx accessible for biopsy

          3. Clinical stage II, III, or IVA disease without distant metastasis, as defined by the
             American Joint Committee on Cancer Staging System, Seventh edition.

          4. Definitive therapy to include surgical resection or chemoradiation for curative
             purposes

          5. Life expectancy o f greater than 6 months

          6. Eastern Cooperative Oncology Group ( ECOG) performance status of 0 or 1

          7. Willing and able to provide written informed consent

        EXCLUSION CRITERIA:

        Participants who meet any of the following criteria are not eligible for enrollment:

          1. Surgical resection or chemoradiation of the HNSCC is contraindicated

          2. Prior head or neck squamous cell carcinoma within 5 years, except for previously
             treated skin cancer

          3. Received chemotherapy targeted monoclonal antibody therapy or investigational therapy
             within 30 days prior to enrollment

          4. Previous radiation therapy to the head or neck

          5. No measurable tumor remaining after prior biopsy or negative margins from prior biopsy

          6. Inadequate hematologic, renal or liver function within l4 days prior to the first
             rapamycin dosing visit, as defined by:

               1. Absolute neutrophil count less than 1.5 times 10 (9)/L

               2. CD4 count &lt; 400 (to account for natural fluctuations in CD4 levels, participants
                  with at least one CD4 count (Bullet) 400 within 14 days prior to dosing will not
                  be excluded)

               3. Platelet count less than 100 times 10(9)/L

               4. Hemoglobin less than l0 g/dL (eligibility level for hemoglobin may be reached by
                  transfusion)

               5. AST, ALT or bilirubin greater than 1.5 times the upper limit of local lab normal
                  values

               6. Total cholesterol level greater than 350 mg/dL

               7. Triglyceride level greater than 400 mg/dL

               8. International Normalized Ratio (INR) greater than 1.5

               9. Serum creatinine greater than 1.5mg/dL

          7. Active hepatitis or HBV or HCV infection

          8. Women who are pregnant or lactating (female of child-bearing age must be abstinent or
             use a barrier type birth control method throughout the study)

          9. Presence of any contraindications to rapamycin therapy, including HlV-protease
             inhibitors and drugs or agents that are modulators of cytochrome P-450 3A4 (CYP3A4)
             and p-glycoprotein(P-gp)

         10. Hypersensitivity to rapamycin

        11 .Has received live vaccine (such as influenza nasal vaccine measles mumps, rubella, oral
        polio, B CG, yellow fever, varicella, or TY2la typhoid) in the past 30 days or has plans to
        take a live vaccine in the next 3 months

        12. Any cognitive impairment that limits the subject s or the subject s legally authorized
        representative s ability to understand the protocol, provide informed consent or assent, or
        to comply with the protocol procedures

        13.Unable or unwilling to comply with the requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice S Lee, DDS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Dental and Craniofacial Research (NIDCR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2010-D-0180.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001 Dec 27;345(26):1890-900. Review. Erratum in: N Engl J Med 2002 Mar 7;346(10):788.</citation>
    <PMID>11756581</PMID>
  </reference>
  <reference>
    <citation>Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol. 2007 Jun 1;25(16):2184-90.</citation>
    <PMID>17538163</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <results_first_submitted>October 27, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2017</results_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Oral Cancer</keyword>
  <keyword>mTOR Inhibitors</keyword>
  <keyword>Targeted Therapies</keyword>
  <keyword>Signal Transduction Inhibitors</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Tongue Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the National Institute of Health (NIH) as well as the Medical University of South Carolina (MUSC). Recruitment began 5/16/2011 with a total of 37 subjects consented; 34 at MUSC and 3 and NIH. Of the 37 consented, 16 subjects received study intervention and completed the study.</recruitment_details>
      <pre_assignment_details>37 participants signed consent, 16 participants received study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus</title>
          <description>Rapamycin (sirolimus), dispensed as either tablets or an oral solution for patients with dysphagia was administered orally as a single loading dose of 15 mg on the first day and 5 mg once a day for the next 20 days. Dose reductions to 3 mg by mouth once per day were implemented if levels of rapamycin &gt; 20 ng/ml occurred on Days 8 or 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus</title>
          <description>Rapamycin (sirolimus), which will be dispensed as either tablets or an oral solution for patients with dysphagia (see Section 0), will be administered orally as a single loading dose of 15 mg on the first day and 5 mg once a day for the next 20 days. Serum rapamycin levels will be obtained on Days 8, 15, 22, and 28 (if rapamycin is &gt; 3 ng/ml at Day 28, the subject will return daily, or as is convenient, for testing until rapamycin is ≤ 3 ng/ml). Dose reduction to 3 mg by mouth once per day will occur if trough levels of rapamycin &gt; 20 ng/ml occur on Days 8 or 15 (see Appendix A, Study Calendar for visit windows). If a dose is decreased at Day 8, it will not be increased at Day 15 regardless of serum rapamycin levels. If subjects receiving 3 mg have levels &gt; 20 ng/ml at Day 15, rapamycin will be reduced to 2 mg once per day. Rapamycin will cease on Day 21 regardless of level.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent (%) Change in Levels of pS6, pAKt473, and Ki-67</title>
        <time_frame>21 days post treatment with rapamycin</time_frame>
        <population>paraffin embedded formalin fixed tissues including head and neck cancer lesion were not available for 2 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Rapamycin (sirolimus), which will be dispensed as either tablets or an oral solution for patients with dysphagia (see Section 0), will be administered orally as a single loading dose of 15 mg on the first day and 5 mg once a day for the next 20 days. Serum rapamycin levels will be obtained on Days 8, 15, 22, and 28 (if rapamycin is &gt; 3 ng/ml at Day 28, the subject will return daily, or as is convenient, for testing until rapamycin is ≤ 3 ng/ml). Dose reduction to 3 mg by mouth once per day will occur if trough levels of rapamycin &gt; 20 ng/ml occur on Days 8 or 15 (see Appendix A, Study Calendar for visit windows). If a dose is decreased at Day 8, it will not be increased at Day 15 regardless of serum rapamycin levels. If subjects receiving 3 mg have levels &gt; 20 ng/ml at Day 15, rapamycin will be reduced to 2 mg once per day. Rapamycin will cease on Day 21 regardless of level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent (%) Change in Levels of pS6, pAKt473, and Ki-67</title>
          <population>paraffin embedded formalin fixed tissues including head and neck cancer lesion were not available for 2 participants</population>
          <units>percentage of change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pS6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.60" spread="18.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pAKt473</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.24" spread="34.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ki-67</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.48" spread="35.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pERK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" spread="104.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent (%) Changes in Tumor Size, Blood Flow, and Standardized Uptake Value</title>
        <time_frame>21 days post treatment with rapamycin</time_frame>
        <population>It was not possible to obtain appropriate CT scans or SUV measurement from all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Rapamycin (sirolimus), which will be dispensed as either tablets or an oral solution for patients with dysphagia (see Section 0), will be administered orally as a single loading dose of 15 mg on the first day and 5 mg once a day for the next 20 days. Serum rapamycin levels will be obtained on Days 8, 15, 22, and 28 (if rapamycin is &gt; 3 ng/ml at Day 28, the subject will return daily, or as is convenient, for testing until rapamycin is ≤ 3 ng/ml). Dose reduction to 3 mg by mouth once per day will occur if trough levels of rapamycin &gt; 20 ng/ml occur on Days 8 or 15 (see Appendix A, Study Calendar for visit windows). If a dose is decreased at Day 8, it will not be increased at Day 15 regardless of serum rapamycin levels. If subjects receiving 3 mg have levels &gt; 20 ng/ml at Day 15, rapamycin will be reduced to 2 mg once per day. Rapamycin will cease on Day 21 regardless of level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent (%) Changes in Tumor Size, Blood Flow, and Standardized Uptake Value</title>
          <population>It was not possible to obtain appropriate CT scans or SUV measurement from all participants</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumor size by CT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.75" spread="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUV non-nodal target lesions</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.84" spread="27.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUV lymph nodes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.01" spread="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent (%) Change in Clinical and Laboratory Evaluations for Safety</title>
        <time_frame>Percent (%) change from Pre to Post treatement (~21 days)</time_frame>
        <population>Same sample loss during processing for phosphor and magnesium</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus</title>
            <description>Rapamycin (sirolimus), which will be dispensed as either tablets or an oral solution for patients with dysphagia (see Section 0), will be administered orally as a single loading dose of 15 mg on the first day and 5 mg once a day for the next 20 days. Serum rapamycin levels will be obtained on Days 8, 15, 22, and 28 (if rapamycin is &gt; 3 ng/ml at Day 28, the subject will return daily, or as is convenient, for testing until rapamycin is ≤ 3 ng/ml). Dose reduction to 3 mg by mouth once per day will occur if trough levels of rapamycin &gt; 20 ng/ml occur on Days 8 or 15 (see Appendix A, Study Calendar for visit windows). If a dose is decreased at Day 8, it will not be increased at Day 15 regardless of serum rapamycin levels. If subjects receiving 3 mg have levels &gt; 20 ng/ml at Day 15, rapamycin will be reduced to 2 mg once per day. Rapamycin will cease on Day 21 regardless of level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent (%) Change in Clinical and Laboratory Evaluations for Safety</title>
          <population>Same sample loss during processing for phosphor and magnesium</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.51" spread="13.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.71" spread="6.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HGB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.32" spread="6.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCH</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="1.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="2.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="5.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLAT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.10" spread="18.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="6.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RDW</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.19" spread="2.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.31" spread="11.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="32.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ca</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.80" spread="2.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cl</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="8.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREATININE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.31" spread="10.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLUCOSE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.28" spread="37.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="9.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" spread="7.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Na</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="1.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PHOSPHOR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.58" spread="16.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of consent to one year post treatment.</time_frame>
      <desc>Subjects were followed 360 days after treatment, surgical or chemo radiation, to assess survival, recurrence of disease, metastases and adverse events that were related to rapamycin therapy including complications of wound healing, infections due to immune compromise and late radiation toxicities.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus</title>
          <description>Rapamycin (sirolimus), which will be dispensed as either tablets or an oral solution for patients with dysphagia (see Section 0), will be administered orally as a single loading dose of 15 mg on the first day and 5 mg once a day for the next 20 days. Serum rapamycin levels will be obtained on Days 8, 15, 22, and 28 (if rapamycin is &gt; 3 ng/ml at Day 28, the subject will return daily, or as is convenient, for testing until rapamycin is ≤ 3 ng/ml). Dose reduction to 3 mg by mouth once per day will occur if trough levels of rapamycin &gt; 20 ng/ml occur on Days 8 or 15 (see Appendix A, Study Calendar for visit windows). If a dose is decreased at Day 8, it will not be increased at Day 15 regardless of serum rapamycin levels. If subjects receiving 3 mg have levels &gt; 20 ng/ml at Day 15, rapamycin will be reduced to 2 mg once per day. Rapamycin will cease on Day 21 regardless of level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE Version 4.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <description>Left Bundle Branch Block diagnosed on routine stress test. Subject had left heart catheterization with stent placement.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Injury, procedural complications/postoperative wound complication</sub_title>
                <description>Orocutaneous fistula with left leg epidermolysis. Jaw hardware candida infection, surgical flap necrosis/failure.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Injury, procedural complications/post-operative wound complication</sub_title>
                <description>Subject had an active bleed from the original tonsillectomy site intraoperative which necessitated extended intubation to postoperative Day 2 when the subject was successfully extubated without further bleeding or complications.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE Version 4.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Thrombocytopenia Neutropenia Anemia Leukopenia</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>Coronary artery disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Combined events reported: vomiting, dysphagia, nausea, oral pain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders and administration site conditions</sub_title>
                <description>Combined: mucosal inflammation, pain, pyrexia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, and procedural complications</sub_title>
                <description>Combined: postoperative wound complications and post procedural hemorrhage</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Combined decreased: neutrophil count, phosphorous, potassium, white blood cell, platelet.
Combined increased: ALT, AST. BUN, glucose, BUN, hepatic enzymes, monocyte count</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Combined: dehydration, hyperglycemia, hypoalbuminaemia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Combined headache, dizziness, hypogeusia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Combined: oropharyngeal pain, nasal congestion</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <description>Combined: photosensitivity and rash</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>D. J. Silvio Gutkind</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>(858) 534 5980</phone>
      <email>sgutkind@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

